Please login to the form below

Not currently logged in
Email:
Password:

NPS

This page shows the latest NPS news and features for those working in and with pharma, biotech and healthcare.

Merck’s backing of NGM Bio yields NASH drug deal

Merck’s backing of NGM Bio yields NASH drug deal

The lead NASH candidate at that time was NP 201, but seems to have been leapfrogged by NGM313, now renamed MK-3655.

Latest news

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Digital mania - a question of value Digital mania - a question of value

    So bad in fact, that the best Net Promoter Score (NPS) is a whopping -40% (minus!).

  • A rare talent A rare talent

    $6bn deal that was completed in January 2016. Before that the firm had a busy 2015, buying US rare disease-focused biotech NPS Pharma for $5.2bn and rare disease and

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome.

  • Pharma deals during January 2015 Pharma deals during January 2015

    Top of the table was the all cash acquisition of NPS Pharmaceuticals by Shire for a total of $5.2bn just one year on from its acquisition of ViroPharma.

  • Pharma deals during June 2014 Pharma deals during June 2014

    Hot gossip. Rumours were posted by the Financial Times that Shire was about to make a $5bn bid for NPS Pharmaceuticals. ... So strong were the rumours that this led to NPS issuing an official denial.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn. ... Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America

  • CRISPR Therapeutics appoints Dr Tony Coles CRISPR Therapeutics appoints Dr Tony Coles

    He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck &Co.

  • Patrick Fabbio named CFO at electroCore Patrick Fabbio named CFO at electroCore

    He joins from NPS Pharmaceuticals where he was VP finance. US-based electroceutical healthcare company electroCore has named Patrick Fabbio as chief financial officer. ... Fabbio has over 20 years of financial leadership experience in public and private

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Packer Forbes News March 2016

    The international Think Again. Think NP-C campaign, which encourages clinicians to recognise and link the symptoms of the rare and devastating disease, Niemann-Pick Type C (NP-C), has been ... Think NP-C has been acknowledged for its significant impact

  • Packer Forbes News December 2015

    Think NP-C’ campaign, the Packer Forbes team in collaboration with the INPDA and Actelion were delighted to be shortlisted as a finalist for the prestigious Pharmaceutical Market Excellence Awards (PMEA) ... Think NP-C’ campaign, which works towards

  • Four Health Communications

    We are particularly proud to have launched European HIV-Hepatitis Testing Week and Think Again, Think NP-C, which have been independently recognised with industry awards and, more importantly, improved the

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics